EXPRESSION OF THE ADHESION MOLECULES ICAM-1 AND ICAM-2 ON TUMOR-CELL LINES DOES NOT CORRELATE WITH THEIR SUSCEPTIBILITY TO NATURAL-KILLER CELL-MEDIATED CYTOLYSIS - EVIDENCE FOR ADDITIONAL LIGANDS FOR EFFECTOR CELL BETA-2 INTEGRINS

被引:23
作者
AKELLA, R
HALL, RE
机构
[1] Guthrie Clinic, Medical Center, Sayre
[2] Department of Medicine, University of Tennessee Medical Center, Knoxville, Tennessee
关键词
D O I
10.1002/eji.1830220429
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The LFA-1 molecule (CD11a/CD18), a member of the leukocyte (beta-2) integrin subfamily of the integrin supergene family, has been shown to subserve important function(s) in natural killer (NK) and lymphokine-activated killer (LAK) effector cells based on monoclonal antibody inhibition and other studies. Presently, two cellular ligands for LFA- 1 have been identified, termed ICAM-1 and ICAM-2. In this study, we have examined the role of target cell ICAM- 1 (CD54) and ICAM-2 in NK-mediated target lysis. Using a panel of tumor target cell lines, ICAM-1 surface protein and transcript expression did not correlate with sensitivity to NK lysis. Compared to ICAM-1, ICAM-2 transcript expression was very low or undetectable in tumor cell targets, and also did not correlate with sensitivity to NK lysis. ICAM-1+ K562 cells and K562 cells which were rendered surface ICAM-1- with an antisense oligonucleotide were equally sensitive to NK lysis. Finally, human ICAM-1- P815 cells were stably transfected with the human ICAM-1 gene, and both ICAM-1- P815 (wild type) and ICAM-1+ stable transfectants were equally insensitive to NK lysis. These studies provide evidence that ICAM-1 and ICAM-2 are not important target cell ligands for NK effector cell LFA-1 and that other target cell ICAM may exist.
引用
收藏
页码:1069 / 1074
页数:6
相关论文
共 42 条
[1]   NUCLEOTIDE-SEQUENCE OF THE CDNA FOR MURINE INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1) [J].
BALLANTYNE, CM ;
OBRIEN, WE ;
BEAUDET, AL .
NUCLEIC ACIDS RESEARCH, 1989, 17 (14) :5853-5853
[2]   ANTI-MAC-1 SELECTIVELY INHIBITS THE MOUSE AND HUMAN TYPE 3 COMPLEMENT RECEPTOR [J].
BELLER, DI ;
SPRINGER, TA ;
SCHREIBER, RD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 156 (04) :1000-1009
[3]  
BIASSONI R, 1988, J IMMUNOL, V140, P1685
[4]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[5]   CHARACTERIZATION OF ICAM-2 AND EVIDENCE FOR A 3RD COUNTER-RECEPTOR FOR LFA-1 [J].
DEFOUGEROLLES, AR ;
STACKER, SA ;
SCHWARTING, R ;
SPRINGER, TA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (01) :253-267
[6]   ICAM-1 (CD54) - A COUNTER-RECEPTOR FOR MAC-1 (CD11B CD18) [J].
DIAMOND, MS ;
STAUNTON, DE ;
DEFOUGEROLLES, AR ;
STACKER, SA ;
GARCIAAGUILAR, J ;
HIBBS, ML ;
SPRINGER, TA .
JOURNAL OF CELL BIOLOGY, 1990, 111 (06) :3129-3139
[7]  
DUSTIN ML, 1986, J IMMUNOL, V137, P245
[8]  
FERRINI S, 1987, J IMMUNOL, V138, P1297
[9]   NEW TECHNIQUE FOR ASSAY OF INFECTIVITY OF HUMAN ADENOVIRUS 5 DNA [J].
GRAHAM, FL ;
VANDEREB, AJ .
VIROLOGY, 1973, 52 (02) :456-467
[10]  
GRANT AJ, 1989, IMMUNOLOGY, V66, P117